Two 5-bagger health tech ASX shares ready to rocket again: expert

These stocks have risen 727% and 456% over the past five years, but one advisor reckons they're about to take off once more.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There is no getting around the fact that ASX growth shares have performed terribly this year.

However, over the longer term, as the market works its way through entire economic cycles, a business can grow sufficiently to eventually put investors ahead.

Some ASX shares involved in health technology are prime examples. 

Those companies have a foot each in two sectors that have been hammered in 2022. But a long-term perspective might prove fruitful, as is the case with these two stocks:

Long-term growth and short-term defence

Imaging software provider Pro Medicus Limited (ASX: PME) has seen its shares dive 11.5% year to date.

However, over the past five years, its shareholders have been celebrating a remarkable 727% rise in their investments, excluding dividends.

For Medallion Financial Group private client advisor Stuart Bromley, the stock is both a long-term growth story and a short-term defensive holding.

"We believe future growth justifies a relatively high price-earnings ratio," Bromley told The Bull.

"Existing clients are renewing contracts, providing Pro Medicus with defensive, long-term revenues."

In recommending the ASX share as a buy, Bromley noted the 2022 financial year saw underlying revenue increase 38% to $93.5 million.

"This medical imaging technology business is taking impressive market share, primarily at the top end of the big and lucrative US market."

Admittedly other professionals are more lukewarm on Pro Medicus than Bromley. According to CMC Markets, eight out of 13 analysts currently rate the health tech stock as a hold.

New CEO from big pharma

The Polynovo Ltd (ASX: PNV) share price has plunged more than 8% since mid-August.

But, similar to Pro Medicus, it has rewarded investors handsomely over the long term. The ASX share has rocketed up 456% over the past five years.

"The company provides dermal regeneration solutions via its NovoSorb biodegradable polymer technology," said Bromley.

"The company posted unaudited record first quarter sales of $12.5 million in fiscal year 2023."

For Bromley, a big catalyst and endorsement for Polynovo shares came a few months ago.

"We're encouraged that Swami Raote, a former US Johnson & Johnson (NYSE: JNJ) veteran of 30 years, was appointed chief executive in July," he said.

"Raote brings a lot of connections to Polynovo."

The advisor admitted Polynovo has had a long run as a cash-burning business, but he can see the light at the end of the tunnel.

"Breakeven is now closer for this business, with a net loss after tax of just $1.19 million in fiscal year 2022."

Bromley's peers are more convinced about this ASX share, with four out of five analysts currently surveyed on CMC Markets recommending Polynovo as a strong buy.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO and Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »